Poly Medicure's Q4 profit drops 7% standalone, 29% consolidated on acquisition costs
Standalone net profit slipped to ₹8,062 lacs while consolidated profit took a 29% hit from deal-related expenses. Full-year standalone profit rose just 1.4%.
— 3 earlier stories on Poly Medicure Ltd. →What's new
- Poly Medicure's standalone Q4 net profit fell ~7% year-on-year to ₹8,062 lacs.
- Consolidated Q4 profit dropped ~29% due to costs from recent acquisitions.
- Full-year standalone profit grew just ~1.4% to ₹33,598 lacs.
Why this matters
The standalone results show a business with mild top-line pressure. The consolidated figure, however, is where the acquisition costs hit, dragging the final quarter's performance. A ~1.4% full-year profit increase against a ~29% Q4 consolidated decline isolates the deal impact to the final period.
What we're watching
- Whether acquisition costs persist as a drag on consolidated margins in coming quarters.
- If the standalone business can return to growth after the weak Q4.
- Management commentary on when deal-related expenses normalize.
The full read
Poly Medicure's standalone Q4 net profit slipped ~7% to ₹8,062 lacs, but the real story is in the consolidated numbers. Those fell ~29% because of costs tied to recent acquisitions. For the full year, standalone profit managed a ~1.4% increase to ₹33,598 lacs, but the final quarter's weakness capped the growth. The dividend stays at ₹3.5 per share. The filing is routine; there are no major surprises or new guidance. The open question is how long those deal costs will weigh on the consolidated books before any acquisition-related expenses normalize.
Questions answered
- Why did consolidated profit fall much more than standalone?
- The consolidated results included acquisition-related costs that did not appear in the standalone books. These deal expenses caused the ~29% year-on-year drop in consolidated Q4 profit.
- How did the full-year profit turn out?
- For the full year, standalone net profit rose ~1.4% to ₹33,598 lacs. Growth was muted because the weak fourth quarter offset earlier gains.
- Is the dividend changing?
- No. The board recommended a dividend of ₹3.5 per share, consistent with historical payouts.
- What does this mean for analyst models?
- There are no major surprises or guidance revisions. The results were anticipated, so forecasts are unlikely to need significant changes.
Poly Medicure Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on POLYMED →- 25 May 2026 · 4:42 PM IST Poly Medicure's Q4 profit drops 7% standalone, 29% consolidated on acquisition costs
- 46d ago Poly Medicure's Q4 profit drops 29% as acquisition costs bite
- 46d ago Poly Medicure walks back PendraCare revenue, renal growth targets
- 46d ago Poly Medicure profit slips in Q4, hit by acquisition costs